{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:56:41Z","timestamp":1761929801842},"reference-count":32,"publisher":"Informa UK Limited","issue":"15","license":[{"start":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T00:00:00Z","timestamp":1461110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"CTI Biopharma Corp"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2016,8,31]]},"DOI":"10.2217\/fon-2016-0137","type":"journal-article","created":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T08:21:34Z","timestamp":1461140494000},"page":"1759-1768","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Pixantrone\u2013Rituximab Versus Gemcitabine\u2013Rituximab In Relapsed\/Refractory Aggressive Non-Hodgkin Lymphoma"],"prefix":"10.1080","volume":"12","author":[{"given":"David","family":"Belada","sequence":"first","affiliation":[{"name":"4th Department of Internal Medicine \u2013 Hematology, Charles University Hospital & Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pencho","family":"Georgiev","sequence":"additional","affiliation":[{"name":"UMHAT \u201cSveti Georgi\u201d, Plovdiv, Clinical Haematology Clinic, Plovdiv, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker","family":"Dakhil","sequence":"additional","affiliation":[{"name":"Cancer Center of Kansas, Wichita, KS, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lowell F","family":"Inhorn","sequence":"additional","affiliation":[{"name":"Blue Ridge Cancer Care, Roanoke, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Andorsky","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Center, Boulder, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Thaddeus","family":"Beck","sequence":"additional","affiliation":[{"name":"Highlands Oncology Group, Fayetteville, AR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Quick","sequence":"additional","affiliation":[{"name":"Joe Arrington Cancer Research & Treatment Center, Lubbock, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Pettengell","sequence":"additional","affiliation":[{"name":"St George\u2019s Healthcare NHS Trust, Tooting, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Daly","sequence":"additional","affiliation":[{"name":"CTI Biopharma Corp., Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P","family":"Dean","sequence":"additional","affiliation":[{"name":"CTI Biopharma Corp., Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariya","family":"Pavlyuk","sequence":"additional","affiliation":[{"name":"Institut de Recherches Internationales Servier, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Failloux","sequence":"additional","affiliation":[{"name":"Institut de Recherches Internationales Servier, Suresnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"H\u00fcbel","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,4,20]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S34055"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1010505"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_3_4_6_1","unstructured":"EUCAN\n. Cancer factsheet. Non-Hodgkin lymphoma. http:\/\/eco.iarc.fr\/eucan\/Cancer.aspx?Cancer=38"},{"key":"e_1_3_4_7_1","unstructured":"National Cancer Institute\n. SEER stat facts sheets: non-Hodgkin lymphoma. http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html"},{"key":"e_1_3_4_8_1","unstructured":"American Cancer Society\n. Global cancer facts and figures 3rd edition. www.cancer.org\/acs\/groups\/content\/@research\/documents\/document\/acspc-044738.pdf"},{"key":"e_1_3_4_9_1","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project Blood 89 3909\u20133918 (1997)","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902895715"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S34273"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.1.96"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp700"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.228650"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-13-A147"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70212-7"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0020"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0579.2004.00340.x-i1"},{"key":"e_1_3_4_21_1","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study","volume":"92","author":"Coiffier B","year":"1998","unstructured":"Coiffier B , HaiounC, KettererNet al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood92, 1927\u20131932 (1998).","journal-title":"Blood"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh176"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14101"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3786"},{"key":"e_1_3_4_25_1","unstructured":"NCCN\n. National Comprehensive Cancer Netork Clinical Practice Guideline (NCCN Guidelines). www.nccn.org"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400007540"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1517\/14796694.1.1.7"},{"key":"e_1_3_4_28_1","unstructured":"US FDA\n. Gemzar: highlights of prescribing information. www.accessdata.fda.gov"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1702-0"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-0941-9"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02795.x"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.015"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000215061.78189.4e"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2016-0137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:19Z","timestamp":1719124999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2016-0137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":32,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,8,31]]}},"alternative-id":["10.2217\/fon-2016-0137"],"URL":"https:\/\/doi.org\/10.2217\/fon-2016-0137","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}